- Home
- FIVN vs VRDN Comparison
FIVN vs VRDN Comparison
Compare FIVN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVN | VRDN |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FIVN | VRDN |
|---|---|---|
| Price | $20.87 | $16.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 14 |
| Target Price | $26.06 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 3.4M | 2.9M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,149,088,000.00 | $5,706,000.00 |
| Revenue This Year | $11.39 | $13.73 |
| Revenue Next Year | $10.00 | $279.00 |
| P/E Ratio | $99.24 | ★ N/A |
| Revenue Growth | ★ 10.28 | N/A |
| 52 Week Low | $13.29 | $12.13 |
| 52 Week High | $30.35 | $34.29 |
Technical Indicators
Market Signals| Indicator | FIVN | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 60.82 | 50.24 |
| Support Level | $20.49 | $15.68 |
| Resistance Level | $22.08 | $19.54 |
| Average True Range (ATR) | 1.47 | 0.86 |
| MACD | 0.30 | 0.79 |
| Stochastic Oscillator | 57.14 | 54.11 |
Price Performance
Historical ComparisonAbout FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.